EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Curexo Inc (060280) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Curexo Inc KRW 1,013, price KRW 7,750, upside -86.9%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Consumer Non-Cyclicals · KR · ISIN KR7060280005

CI Thin data Sep 24, 2026

Curexo Inc

060280 · KQ

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value 1,013 KRW · Strongly overvalued (−87%)
!Quality 59/100
!Mixed Growth (revenue 5y +13.7 %/yr)
!Loss over the last twelve months · -58.0% net margin (TTM) · fiscal year 2025 3.7%
!Low debt · negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
!Weak on future: 22 out of 100
Watch Curexo Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

24,400 KRW 5,610 KRW Fair Value 1,013 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 5,610 KRW – 24,400 KRW · fair‑value band 806.28 KRW – 1,317 KRW · the 7,750 KRW price screens above the 1,013 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Curexo in your weekly email

Every Wednesday you see whether Curexo is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Curexo Inc. engages in the development and sale of medical devices in Korea and internationally.

Show more

Curexo Inc. engages in the development and sale of medical devices in Korea and internationally. Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and Gait rehabilitation robot. The company also imports, distributes, and sells food and food additives. Curexo Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

Stock analysis

Curexo Inc (060280) currently trades at 7,750 KRW, while our model-based Fair Value estimate is 1,013 KRW, implying the stock looks roughly 665.1% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 1,762 KRW per share, and 0 of the 15 models we run sit above the 7,750 KRW price.

Bear case: the Economic Profit group reads lowest at 868.65 KRW, and 15 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 806.28 KRW (bear) to 1,317 KRW (bull), the price of 7,750 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Consumer Non-Cyclicals sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Curexo Inc reported revenue of 74.5B KRW in FY2025 versus 42.8B KRW in FY2021, a compound +14.9%/yr. Reported net income was 2.8B KRW in FY2025.

Key figures

Market cap 318B KRW (≈ $223M) · P/S ratio 12.2 · Net margin 3.7% · Return on equity −744% · Return on assets (EBIT) −2.2% · Operating margin −153% · Revenue (TTM) 27.8B KRW · Revenue growth (YoY) +4.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −31% fair-value upside, at −87%, 060280 screens richer than that median.

Fair Value models

Bear 806.28 KRW Fair Value 1,013 KRW Bull 1,317 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 1,212 KRW 1,762 KRW 2,616 KRW 75
EPV 824.31 KRW 868.65 KRW 904.64 KRW 72
ROIC Compounder 824.31 KRW 868.65 KRW 904.64 KRW 71
All 15 models by family
DCF Models
Owner Earnings 1,212 KRW 1,762 KRW 2,616 KRW 75
Earnings-Based
Graham-Dodd 458.65 KRW 2,542 KRW 3,528 KRW 61
Lynch FV 709.16 KRW 1,013 KRW 1,317 KRW 58
PEG = 1.0 709.16 KRW 1,013 KRW 1,317 KRW 55
EPV 824.31 KRW 868.65 KRW 904.64 KRW 72
Multiples
P/E Multiple 1,113 KRW 1,484 KRW 1,855 KRW 61
P/S Multiple 859.98 KRW 1,147 KRW 1,433 KRW 56
P/B Multiple 859.98 KRW 1,147 KRW 1,433 KRW 53
EV/EBIT 1,188 KRW 1,432 KRW 1,676 KRW 65
EV/EBITDA 1,770 KRW 2,209 KRW 2,647 KRW 66
EV/Revenue 977.86 KRW 1,202 KRW 1,426 KRW 53
Asset-Based
NCAV (Graham) 1,171 KRW 1,569 KRW 2,342 KRW 52
Economic Profit
Residual Income 1,517 KRW 1,407 KRW 1,020 KRW 69
ROIC Compounder 824.31 KRW 868.65 KRW 904.64 KRW 71
Growth Earnings
Growth-Adj P/E 1,093 KRW 1,562 KRW 2,031 KRW 66

Open the full fair value analysis →

Notify me when 060280 reaches fair value

Put 060280 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 59/100

Of which business quality 59 · Market factors (momentum, volatility) 22

Profitability 35
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 87
Disciplined investing over empire-building
Low Volatility 30
Calm price path (market factor)
Momentum 21
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 72
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+34.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +10.5% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+40.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+40.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.40% vs −23%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 3%
Start year 2020 (pandemic)

060280 screens 665% overvalued. Compare with PGOLD →

Compare Curexo Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Food & Drug Retailing” was too small, so the broader sector is used.)Health Care · 2614 stocks

Beats the sector median on 2/6 measures
Overall it trails its sector peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −87% · Bottom 25%
Profitability
Return on assets −45% · Bottom 25%
Net margin (TTM) −58% · Bottom 25%
Operating margin (TTM) −153% · Bottom 25%
Growth and dividend
Revenue growth 4% · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)22 · sector 21
PAST (return on equity)0 · sector 13
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Food & Drug Retailing stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
PGOLD PGOLD 40.00 PHP 48.69 PHP +22%
Gimat Magazacilik Sanayi Ve Ticaret A.S. GMTAS 49.02 TRY 7.24 TRY −85%
FRUIT FRUIT 0.6400 PHP 0.5500 PHP −14%
Seouleaguer Co 043710 2,850 KRW 811.29 KRW −72%
Cosco (India) Limited 530545 ₹189.90 ₹58.22 −69%
FB FB 43.40 PHP 39.12 PHP −10%
JGS JGS 18.94 PHP 26.54 PHP +40%
URC URC 58.95 PHP 40.78 PHP −31%
SMC SMC 61.60 PHP 41.22 PHP −33%
MONDE MONDE 6.16 PHP 0.7500 PHP −88%

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Curexo Inc · Fair Value
1,013 KRW −665%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Curexo Inc Fair Value". https://www.fairvalue-calculator.com/stock/060280

Frequently asked questions

Is Curexo Inc (060280) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,013 KRW versus a price of 7,750 KRW, about −87% upside (overvalued).
What is the fair value of 060280?
Our model-based fair value for Curexo Inc is 1,013 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 7,750 KRW.
What is the quality score of 060280?
Curexo Inc has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Curexo Inc (060280)?
Our model-based price target is the fair value of 1,013 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 806.28 KRW, optimistic scenario 1,317 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Curexo Inc stock forecast for 2026?
Our models put fair value at 1,013 KRW, about −87% upside versus a price of 7,750 KRW (overvalued). Cautious scenario 806.28 KRW, optimistic scenario 1,317 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Curexo Inc (060280)?
Curexo Inc reported trailing-twelve-month revenue of about 27.8B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Curexo Inc (060280)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Curexo Inc it is 1,013 KRW per share (as of Sep 24, 2026), against a price of 7,750 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Curexo Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 060280 trades above its calculated fair value: price 7,750 KRW, fair value 1,013 KRW, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 060280?
No. The price is what the market pays today (7,750 KRW); the fair value is what the company's own numbers justify (1,013 KRW). For Curexo Inc the two are 6,737 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Curexo Inc worth?
The market values Curexo Inc at about 318B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 7,750 KRW; our models calculate a fair value of 1,013 KRW per share.
What do the bullish and bearish scenarios say about 060280?
Our models span a range for Curexo Inc: cautious scenario 806.28 KRW, base 1,013 KRW, optimistic 1,317 KRW per share (as of Sep 24, 2026, price 7,750 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 060280 from its 52-week high?
Curexo Inc trades at 7,750 KRW, about 62% below its 52-week high of 20,350 KRW and 7% above the low of 7,260 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,013 KRW is for.
Which stocks are comparable to Curexo Inc?
From the same area (Consumer Non-Cyclicals) we also value PGOLD, Gimat Magazacilik Sanayi Ve Ticaret A.S., FRUIT, Seouleaguer Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Curexo Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 7,750 KRW, calculated fair value 1,013 KRW (−87%), Quality Score 59/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 060280 calculated?
We run Curexo Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,013 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Curexo Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Curexo Inc (060280)?
The closing price on Sep 23, 2026 was 7,750 KRW. Our model-based fair value is 1,013 KRW, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Curexo Inc right now?
The price sits above even our optimistic bull case (1,317 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Curexo Inc

How large is the market capitalisation of Curexo Inc (060280)?
The market capitalisation of Curexo Inc is 318B KRW (≈ $223M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Curexo Inc (060280)?
The price-to-sales ratio of Curexo Inc is 12.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Curexo Inc (060280)?
The net margin of Curexo Inc is 3.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Curexo Inc (060280)?
The return on equity (ROE) of Curexo Inc is −744% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Curexo Inc (060280)?
On an EBIT basis the return on assets of Curexo Inc is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Curexo Inc (060280)?
The operating margin of Curexo Inc is −153% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Curexo Inc (060280)?
Revenue at Curexo Inc is growing +4.3% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Curexo Inc (060280) generate?
The free cash flow of Curexo Inc is −13.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Curexo Inc (060280) carry?
The net debt of Curexo Inc is 5.2B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Curexo Inc in the live analysis

One click puts Curexo Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.